World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
40048
World Ranking
6039
National Ranking
3229

Richard Pazdur publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard Pazdur sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 279 publications — 13th percentile

13% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard Pazdur D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard Pazdur sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 108 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Richard Pazdur is affiliated with the US Food and Drug Administration in the United States. Their research is primarily focused on medicine, with a strong emphasis on oncology and related subfields.

Their work spans multiple subfields including:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Economics and Econometrics
  • Surgery

Richard Pazdur's research covers a range of topics, concentrating on:

  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Advanced Breast Cancer Therapies
  • Health Systems, Economic Evaluations, Quality of Life
  • Economic and Financial Impacts of Cancer
  • Lung Cancer Treatments and Mutations
  • Statistical Methods in Clinical Trials

Their publication record includes recent papers such as:

  • FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors, 2021, Clinical Cancer Research
  • FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC, 2021, Clinical Cancer Research
  • The Drug-Dosing Conundrum in Oncology - When Less Is More, 2021, New England Journal of Medicine
  • Trends in the approval of cancer therapies by the FDA in the twenty-first century, 2023, Nature Reviews Drug Discovery
  • FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer, 2022, Clinical Cancer Research

Richard Pazdur frequently collaborates with several coauthors, including:

  • Julia A. Beaver
  • Paul G. Kluetz
  • Marc R. Theoret
  • Shenghui Tang
  • Laleh Amiri-Kordestani

Their work is prominently published in journals such as:

  • Clinical Cancer Research
  • Journal of Clinical Oncology
  • The Oncologist
  • JAMA Oncology
  • Statistics in Biopharmaceutical Research

Best Publications

  • FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

    Bhupinder S. Mann;John R. Johnson;Martin H. Cohen;Robert Justice

  • Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia

    Peter F. Bross;Julie Beitz;Gang Chen;Xiao Hong Chen

  • Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration

    Lilia Talarico;Gang Chen;Richard Pazdur

  • Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy

    Robert C. Kane;Peter F. Bross;Ann T. Farrell;Richard Pazdur

  • FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

    Martin H. Cohen;Yuan Li Shen;Patricia Keegan;Richard Pazdur

  • FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

    Martin H. Cohen;Grant A. Williams;Rajeshwari Sridhara;Gang Chen

  • United States Food and Drug Administration Drug Approval Summary: Gefitinib (ZD1839; Iressa) Tablets

    Martin H. Cohen;Grant A. Williams;Rajeshwari Sridhara;Gang Chen

  • First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.

    Steven Lemery;Patricia Keegan;Richard Pazdur

  • End Points and United States Food and Drug Administration Approval of Oncology Drugs

    John R. Johnson;Grant Williams;Richard Pazdur

  • Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.

    Vicki L. Goodman;Edwin P. Rock;Ramzi Dagher;Roshni P. Ramchandani

  • Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

    Martin H. Cohen;Grant Williams;John R. Johnson;John Duan

  • Sorafenib for the Treatment of Advanced Renal Cell Carcinoma

    Robert C. Kane;Ann T. Farrell;Haleh Saber;Shenghui Tang

  • FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension

    Edvardas Kaminskas;Ann T. Farrell;Yong-Cheng Wang;Rajeshwari Sridhara

  • Approval Summary Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors

    Ramzi Dagher;Martin Cohen;Gene Williams;Mark Rothmann

  • Approval summary : azacitidine for treatment of myelodysplastic syndrome subtypes

    Edvardas Kaminskas;Ann Farrell;Sophia Abraham;Amy Baird

  • FDA drug approval summary: erlotinib (Tarceva) tablets.

    Martin H. Cohen;John R. Johnson;Yeh-Fong Chen;Rajeshwari Sridhara

  • FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease†‡§

    Min Lu;Martin H. Cohen;Dwaine Rieves;Richard Pazdur

  • FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

    Dickran Kazandjian;Daniel L. Suzman;Gideon Blumenthal;Sirisha Mushti

  • FDA Drug Approval Summary: Bevacizumab (Avastin®) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell Lung Cancer

    Martin H. Cohen;Joe Gootenberg;Patricia Keegan;Richard Pazdur

  • Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma

    Peter F. Bross;Robert Kane;Ann T. Farrell;Sophia Abraham

Frequent Co-Authors

Donna Przepiorka
Donna Przepiorka US Food and Drug Administration
Richard L. Schilsky
Richard L. Schilsky University of Chicago
Mark J. Ratain
Mark J. Ratain University of Chicago
Jaap Verweij
Jaap Verweij Erasmus University Rotterdam
Lawrence J. Lesko
Lawrence J. Lesko University of Florida
James L. Abbruzzese
James L. Abbruzzese Duke University
Malcolm A. Smith
Malcolm A. Smith National Institutes of Health
Luc Dirix
Luc Dirix GZA Ziekenhuizen Campus Sint-Augustinus
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Ethan Basch
Ethan Basch University of North Carolina at Chapel Hill

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a future in medicine can open doors to a wide variety of related degrees and career pathways. Many students choose to start with a cheapest online health science degree as a foundation. These programs are flexible and affordable, helping you build core knowledge in health and science while allowing you to manage other commitments.

For those aiming for leadership roles, the most affordable mha programs (Master of Healthcare Administration) offer advanced training in healthcare management. These online MHA programs are designed for working professionals and can help you move into higher-level positions in hospitals, clinics, or public health organizations.

If you're interested in advanced nursing practice, some of the best online dnp programs (Doctor of Nursing Practice) offer rigorous, evidence-based training for future clinical leaders and nurse practitioners.

Alternatively, for students seeking expertise in pharmacology, there are accredited online pharmacy schools that provide flexible pathways to a Doctor of Pharmacy degree, preparing graduates for rewarding careers in pharmaceutical care and research.

Best Scientists Citing Richard Pazdur

Trending Scientists